Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines. Presenting below are its Q1 FY26 earnings results.
Q1 FY26 Earnings Results
-
Total Income: ₹406.30 crores, down from ₹535.90 crores in previous quarter and also down by 12.5 percent on the YoY basis.
-
Total Expenses: ₹320.5 crores, down from ₹364 crores in previous quarter and also down by 10.3 percent from the same quarter, last year.
-
Profit Before Tax (PBT): ₹94.50 crores (down from ₹165.60 crores)
-
Profit After Tax (PAT): ₹69.50 crores, down from ₹172 crores in the previous quarter and also down by 32.4 percent on the YoY basis.
-
EBIT (Earnings Before Interest & Tax): ₹94.50 crores
-
EBIT Margin: Approximately 22.77%
-
Net Profit Margin: Approximately 17.24%
-
Basic EPS: ₹30.22, a decline of 32.7 percent on the YoY basis
Management Commentary & Strategic Highlights:
-
Sanofi India reported a 32% decline in profit for Q1 FY26 compared to Q1 FY25, mainly due to lower sales and higher input costs.
-
The company continues its focus on strengthening its product portfolio, especially in specialty care including diabetes and cardiovascular medicines.
-
Sanofi India’s strategic focus remains on innovation, expanding market share in niche segments, and improving operational efficiencies.
-
Emphasis on increasing footprint in emerging therapies and making investments in R&D and marketing.
-
Management highlighted navigating competitive pressures and economic headwinds while staying committed to growth and sustainable profitability.
Q4 FY25 Earnings Results
-
Total Income: ₹536 crores, up by 4.89 percent on the YoY basis.
-
Total Expenses: ₹364 crores, down by 2.6 percent on the YoY basis.
-
Profit After Tax (PAT): ₹120 crores, down by 12.4 percent from the same quarter, last year
-
EBIT: ₹165.60 crores
-
EBIT Margin: Approximately 30.71%
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,